Form 4: Director Jason Haas Receives Equity Grant at Ligand

Ligand Pharmaceuticals director Jason Haas was granted 836 restricted stock units and 2,938 stock options as part of an annual board compensation package.

Summary

• Director Jason Haas acquired 836 restricted stock units (RSUs) on June 5, 2026.
• Director Jason Haas was granted 2,938 non-qualified stock options with an exercise price of $237 per share.
• The equity grants were awarded by the Board of Directors during the annual meeting.
• The total beneficial ownership for Jason Haas following these transactions is 7,442 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized vesting schedule ensures long-term commitment to the company.

Negatives

• Dilutive impact of new equity grants, though minor in scale.

Risks

• Market price volatility affecting the value of the granted stock options.
• Vesting is contingent upon continued service as a director.

Future Outlook

The equity grants vest on the earlier of the next annual meeting or the first anniversary of the grant date, signaling expected continued board service.

Management Comments

• The grants were awarded by the Board of Directors at their annual meeting on June 5, 2026.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard practices for mid-cap pharmaceutical companies.
• Vesting schedules tied to annual meetings are common industry practice for board members.

Stakeholder Impact

• Minimal impact on existing shareholders due to the small size of the equity grant.

Next Steps

• Vesting of the RSUs and options on the earlier of the next annual meeting or June 5, 2027.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Equity Compensation, Director Compensation